Organ-sparing multimodality treatment in muscle-invasive bladder cancer

Authors

DOI:

https://doi.org/10.26641/2307-5279.24.3.2020.213463

Keywords:

organ-preserving treatment, muscular-invasive bladder cancer, chemoradiation therapy

Abstract

Goal. Improving short- and long-term cancer outcomes, quality of life, and reduce complication rate after treatment of patients with muscle-invasive bladder cancer by justifying the indications for organ-sparing surgery with adjuvant chemotherapy. Materials and methods. A retrospective analysis of 120 patients who underwent organ-sparing surgery was performed. Patients were divided into 3 groups. In the comparative analysis of the studied groups, the assessment of oncological results, quality of life and postoperative complications Results. Patients who underwent partial cystectomy of bladder with adjuvant chemotherapy, showed better in comparison to two other groups remote oncological results by 20%. The mean follow-up was 6 years. The evaluation of oncological results was performed due to the guidelines of the European Association of Urology for patients with MIBC after organ-preserving multimodality treatment. Indicators of erectile function and quality of life in the main group were better than in two other groups. Conclusions. The presented results of the study suggest that organ-preserving treatment with chemo-radiation therapy of muscle-invasive bladder cancer is an alternative method of treatment.

References

Muscle-invasive and Metastatic Bladder-Cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona. EAU Guidelines Office, Arnhem. The Netherlands. 2019.

Fahmy O., Khairul-Asri M.G., Schubert T. et al. A Systematic Review and Meta-Analysis on the Oncological Long-Term Outcomes After Trimodality Therapy and Radical Cystectomy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Urol Oncol. 2018. Vol. 36, No. 2. P. 43–53.

Ploussard G., Daneshmand S., Efstathiou J.A. et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur. Urol. 2014. Vol. 66. P. 120–137.

Ma B., Li H., Zhang C., Yang K. et al. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes. Eur. J. Surg. Oncol. 2013. Vol. 39. P. 1150–1156. Doi: 10.1016/j.ejso.2013.04.006.

Capitanio U., Isbarn H., Shariat S.H. et al. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology. 2009. Vol. 74. Р. 858–864.

Knoedler J., Frank I. Organ-sparing surgery in urology: partial cystectomy. Curr. Opin. Urol. 2015. Vol. 25. P. 111–115.

Knoedler J.J., Boorjian S.A., Kim S.P. et al. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J. Urol. 2012. Vol. 188. P. 1115–1119.

Smaldone M.C., Jacobs B.L., Smaldone A.M., Hrebinko R.L. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology. 2008. Vol. 72. P. 613–616.

Rudel C., Weiss C., Sauer R. Organ preservation by combined modality treatment in bladder cancer: the European perspective. Semin. Radiat. Oncol. 2005. Vol. 15. P. 28–35.

Chiang Y., Cheng J.C., Huang C.Y. et al. A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement. J Formos Med Assoc. 2017. Vol. 116. P. 689–696.

Leibovici D., Kassouf W., Pisters L.L. et al. NCCN Guidelines 2019: Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology. 2007. Vol. 70, No. 3. P. 473–476.

Mohamed H.А., Salem M.A., Elnaggar M.S. et al. Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine. Cancer Radiother. 2018. Vol. 22, No. 3. P. 236–240. Doi: 10.1016/j.canrad.2017.09.013.

Giacalone N., Shipley W.U., Clayman R.H. et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience Eur Urol. 2017. Vol. 71, No. 6. P. 952–960. Doi: 10.1016/j.eururo.2016.12.020.

Holzbeitrlein J.M., Lopez-Corona E., Bochner B.H. et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J. Urol. 2004. Vol. 172. P. 878–881.

Rudel C., Grabenbauer G.G., Kuhn R. et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer. J Clin Oncol. 2002. Vol. 20, No. 14. P. 3061–3071.

Downloads

Published

2020-10-06

Issue

Vol. 24 No. 3 (2020)

Section

Oncourology

License

Стаття повинна мати візу керівника та офіційне направлення від установи, з якої виходить стаття (з круглою печаткою), і вказівкою, чи є стаття дисертаційною, а також у довільній формі на окремому аркуші - відомості про авторів (прізвище, ім’я, по батькові, посада, вчений ступінь, місце роботи, адреса, контактні телефони, E-mail).

Стаття повина бути підписана всіма авторами, які укладають з редакцією договір пропередачу авторських прав (заповнюється на кожного автора окремо з оригінальним підписом). За таких умов редакція має право на її публікацію та розміщення на сайті видавництва.